Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sangamo TherapeuticsFRA:GBY Days Payable is 0.00 as of Mar. 2026. The stock has 5 warning signs investors should review. Among 701 Biotechnology companies, Sangamo Therapeutics ranks worse than 142653.21% on this metric.
The historical rank and industry rank for Sangamo Therapeutics's Days Payable or its related term are showing as below:
FRA:GBY's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.36 * Ranked among companies with meaningful Days Payable only.
Sangamo Therapeutics's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
Sangamo Therapeutics Days Payable Related Terms
Sangamo Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Sangamo Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GBY vs SER, ABVC, PLRZ: Days Payable Comparison
For the Biotechnology subindustry, Sangamo Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sangamo Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sangamo Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Sangamo Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sangamo Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sangamo Therapeutics (FRA:GBY) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sangamo Therapeutics and its competitors. According to the industry distribution chart, Sangamo Therapeutics ranks #999999 out of 701 companies in the Biotechnology industry.
Is Sangamo Therapeutics' Days Payable too high?
Sangamo Therapeutics' current Days Payable is 0.00. Based on the distribution chart, Sangamo Therapeutics ranks #999999 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Sangamo Therapeutics' Days Payable compare to SER and ABVC?
According to the Biotechnology industry distribution chart, Sangamo Therapeutics ranks #999999 out of 701 companies for Days Payable. This places Sangamo Therapeutics in the lower half of its industry. The industry median Days Payable is 113.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sangamo Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sangamo Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sangamo Therapeutics stock overvalued right now?
Sangamo Therapeutics (FRA:GBY) has a current Days Payable of 0.00. The stock's GF Value™ is €0.18, compared to a current price of €0.07 — trading 63.2% below its estimated fair value. The current Days Payable is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sangamo Therapeutics (FRA:GBY), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GBY has been successfully added to your 
